Despina Michailidou

Despina Michailidou

Auto-generated profile, based on publicly available information

Despina Michailidou

Division of Rheumatology University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
DMDespina Michailidou
Despina Michailidou
LJLinda Johansson
Linda Johansson
RKRuna Kuley
Runa Kuley
TWTing Wang
Ting Wang
PHPayton Hermanson
Payton Hermanson
CLChristian Lood
Christian Lood
Neutrophils are important in host defence. However, neutrophils are also linked to inflammation and organ damage. The purpose of this study was to assess whether markers of neutrophil activation are increased in PMR. Levels of immune complexes (IC), calprotectin and neutrophil extracellular traps (NETs) were measured in plasma of healthy individuals (n = 30) and patients with PMR (n = 60), at flare and upon treatment with glucocorticoids using ELISA. Plasma-mediated neutrophil activation was assessed in presence of an FcγRIIA inhibitory antibody (IV.3). Plasma levels of calprotectin and NETs were elevated in PMR (P < 0.001). Mechanistically, neutrophil activation was driven by ICs, present in plasma, able to up-regulate neutrophil activation markers CD66b and CD11b (P < 0.0001) in an FcγRIIA-dependent manner (P < 0.01). Of note, circulating levels of IC correlated with plasma induced CD66b and CD11b (r = 0.51, P = 0.004, and r = 0.46, P = 0.01, respectively) and decreased after glucocorticoid therapy. In contrast to NETs, calprotectin significantly decreased after glucocorticoid therapy (P < 0.001) and was higher in PMR without overlapping GCA compared with patients with overlapping disease (P = 0.014). Interestingly, musculoskeletal involvement was associated with elevated levels of calprotectin before initiation of glucocorticoid therapy (P = 0.036). Neutrophil activation, including NET formation, is increased in PMR, through IC-mediated engagement of FcγRIIA. Clinically, neutrophil activation is associated with musculoskeletal involvement, with calprotectin, but not NETs, being a biomarker of treatment response in PMR patients. In all, IC-mediated neutrophil activation is a central process in PMR pathogenesis identifying potential novel therapeutic targets (FcγRIIA), as well as soluble markers for disease monitoring (calprotectin).

4 January 2022 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DMDespina Michailidou
Despina Michailidou
TZTianyu Zhang
Tianyu Zhang
PSPavlos Stamatis
Pavlos Stamatis
BNBernard Ng
Bernard Ng

9 November 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
DMDespina Michailidou
Despina Michailidou
TZTianyu Zhang
Tianyu Zhang
NKNicole M. Kuderer
Nicole M. Kuderer
GLGary H. Lyman
Gary H. Lyman
ADAndreas P. Diamantopoulos
Andreas P. Diamantopoulos
BNBernard Ng
Bernard Ng
Giant cell arteritis (GCA) that affects older patients is an independent risk factor for thromboembolic events. The objective of this study was to identify predictive factors for thromboembolic events in patients with GCA and develop quantitative predictive tools (prognostic nomograms) for pulmonary embolism (PE) and deep venous thrombosis (DVT). A total of 13,029 patients with a GCA diagnosis were included in this retrospective study. We investigated potential predictors of PE and DVT using univariable and multivariable Cox regression models. Nomograms were then constructed based on the results of our Cox models. We also assessed the accuracy and predictive ability of our models by using calibration curves and cross-validation concordance index. Age, inpatient status at the time of initial diagnosis of GCA, number of admissions before diagnosis of GCA, and Charlson comorbidity index were each found to be independent predictive factors of thromboembolic events. Prognostic nomograms were then prepared based on these predictors with promising prognostic ability. The probability of developing thromboembolic events over an observation period of 5 years was estimated by with time-to-event analysis using the method of Kaplan and Meier, after stratifying patients based on predicted risk. The concordance index of the time-to-event analysis for both PE and DVT was > 0.61, indicating a good predictive performance. The proposed nomograms, based on specific predictive factors, can accurately estimate the probability of developing PE or DVT among patients with GCA.

16 December 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
DMDespina Michailidou
Despina Michailidou
SCSarah Chung
Sarah Chung
JAJames S. Andrews
James S. Andrews
GSGordon A. Starkebaum
Gordon A. Starkebaum
FCFelix S. Chew
Felix S. Chew
CLCaitlin S. Latimer
Caitlin S. Latimer

12 March 2025 in ACR Open Rheumatology
Verified
Journal Article
Open access
DMDespina Michailidou
Despina Michailidou
LJLinda Johansson
Linda Johansson
JCJorge Armando Gonzalez Chapa
Jorge Armando Gonzalez Chapa
TWTing Wang
Ting Wang
JCJunmei Chen
Junmei Chen
CLChristian Lood
Christian Lood
Objective: Platelet activation is thought to participate in polymyalgia rheumatica (PMR) pathogenesis. Upon platelet activation, mitochondria are expelled into the extracellular space. However, whether extracellular mitochondria are present in patients with PMR and whether they can induce platelet activation is not known.Methods: To investigate this, we measured markers of platelet activation (thrombospondin‐1 [TSP‐1]), mitochondrial‐derived N‐formyl methionine peptide (fMET), and autoantibodies directed toward specific mitochondrial antigen mitofusin‐1 (MFN1) by enzyme‐linked immunosorbent assay in plasma of healthy controls (HCs, n = 30) and patients with PMR without giant cell arteritis (GCA) (n = 45) and patients with PMR with GCA (n = 9) before and after treatment with glucocorticoid therapy. Ultrapure mitochondria were opsonized with plasma from patients with PMR without GCA (n = 45) or HCs (n = 10) and were subsequently incubated with HC platelets. Platelet activation was assessed by P‐selectin levels using flow cytometry.Results: Plasma levels of anti‐MFN1 IgG were elevated in patients with PMR with and without GCA before glucocorticoid therapy when compared with HCs (P < 0.01 for both groups). Levels of anti‐MFN1 IgG significantly reduced after treatment with glucocorticoids in both groups (P < 0.01). Levels of fMET were also significantly higher in patients with PMR with and without GCA before glucocorticoid therapy in comparison with HCs (P < 0.001 and P < 0.01, respectively). However, the levels of fMET only dropped significantly after therapy in patients with PMR without GCA (P < 0.001). Plasma levels of TSP‐1 were elevated in patients with PMR with and without GCA before glucocorticoid therapy when compared to HC (P < 0.001 for both groups). After glucocorticoid therapy, plasma levels of TSP‐1 decreased significantly only in patients with PMR without GCA (P = 0.023). Mitochondria opsonized with plasma from patients with PMR without GCA induced higher platelet activation regardless of treatment status as compared with plasma from HCs (P < 0.0001 and P < 0.01 for pretreatment and posttreatment).Conclusion: Our results indicate increased platelet activation and the presence of mitochondrial antigens and antibodies in the circulation of patients with PMR. Blocking mitochondrial‐mediated platelet activation may reduce inflammation in patients with PMR, with potential therapeutic implications. image

29 August 2017 in Lupus
Verified
Journal Article
Closed access
DMD Michailidou
D Michailidou
MKM Kribis
M Kribis
RKR Kataria
R Kataria
KSK Sedaliu
K Sedaliu
MDM Dumitrescu
M Dumitrescu
Angioedema has been observed in a few cases secondary to systemic lupus erythematosus (SLE). Herein, we report a rare case where a young healthy male initially presented with angioedema, lymphadenopathy and parotitis and later on developed neuropsychiatric manifestations at the very onset of his SLE disease. This case illustrates the importance of prompt clinical consideration of lupus with unusual and atypical preceding manifestations